Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 64 citing articles:

Targeting CDK4 and CDK6 in cancer
Shom Goel, Johann S. Bergholz, Jean J. Zhao
Nature reviews. Cancer (2022) Vol. 22, Iss. 6, pp. 356-372
Open Access | Times Cited: 321
Drug resistance and Cancer stem cells
Yuan Li, Zhenning Wang, Jaffer A. Ajani, et al.
Cell Communication and Signaling (2021) Vol. 19, Iss. 1
Open Access | Times Cited: 231
Targeted therapy for head and neck cancer: signaling pathways and clinical studies
Qingfang Li, Yan Tie, Aqu Alu, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 130
YAP prevents premature senescence of astrocytes and cognitive decline of Alzheimer's disease through regulating CDK6 signaling
Xingxing Xu, Xiya Shen, Jiaojiao Wang, et al.
Aging Cell (2021) Vol. 20, Iss. 9
Open Access | Times Cited: 65
ALDH1: A potential therapeutic target for cancer stem cells in solid tumors
Yaolu Wei, Yan Li, Yen‐An Chen, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 61
Broad-spectrum kinome profiling identifies CDK6 upregulation as a driver of lenvatinib resistance in hepatocellular carcinoma
Carmen Oi Ning Leung, Yang Yang, Rainbow Wing Hei Leung, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 27
CDK4/6 inhibitors: a novel strategy for tumor radiosensitization
Yilan Yang, Jurui Luo, Xingxing Chen, et al.
Journal of Experimental & Clinical Cancer Research (2020) Vol. 39, Iss. 1
Open Access | Times Cited: 55
Intrinsic and acquired resistance to CDK4/6 inhibitors and potential overcoming strategies
Xiaqing Xu, Xiaohui Pan, Tingting Wang, et al.
Acta Pharmacologica Sinica (2020) Vol. 42, Iss. 2, pp. 171-178
Open Access | Times Cited: 51
Targeting cancer stem cells with a pan-BCL-2 inhibitor in preclinical and clinical settings in patients with gastroesophageal carcinoma
Shumei Song, Qiongrong Chen, Yuan Li, et al.
Gut (2021) Vol. 70, Iss. 12, pp. 2238-2248
Open Access | Times Cited: 46
FTO promotes tumour proliferation in bladder cancer via the FTO/miR-576/CDK6 axis in an m6A-dependent manner
Guanwen Zhou, Keqiang Yan, Ji‐Kai Liu, et al.
Cell Death Discovery (2021) Vol. 7, Iss. 1
Open Access | Times Cited: 41
CDK4/6 Inhibitors in Combination Therapies: Better in Company Than Alone: A Mini Review
Gian Luca Rampioni Vinciguerra, Maura Sonego, Ilenia Segatto, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 30
Abemaciclib Is Effective Against Pancreatic Cancer Cells and Synergizes with HuR and YAP1 Inhibition
Teena Dhir, Christopher W. Schultz, Aditi Jain, et al.
Molecular Cancer Research (2019) Vol. 17, Iss. 10, pp. 2029-2041
Open Access | Times Cited: 43
The feedback loop of ANKHD1/lncRNA MALAT1/YAP1 strengthens the radioresistance of CRC by activating YAP1/AKT signaling
Pingan Yao, Yong Wu, Kui Zhao, et al.
Cell Death and Disease (2022) Vol. 13, Iss. 2
Open Access | Times Cited: 24
Targeting cyclin‐dependent kinase 6 by vanillin inhibits proliferation of breast and lung cancer cells: Combined computational and biochemical studies
Mohd Yousuf, Anas Shamsi, Aarfa Queen, et al.
Journal of Cellular Biochemistry (2021) Vol. 122, Iss. 8, pp. 897-910
Closed Access | Times Cited: 32
Mechanisms and Implications of CDK4/6 Inhibitors for the Treatment of NSCLC
Jinmeng Zhang, Dayu Xu, Yue Zhou, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 32
Inhibiting CBX4 efficiently protects hepatocellular carcinoma cells against sorafenib resistance
Wei Zhao, Bo Ma, Zhihua Tian, et al.
British Journal of Cancer (2021) Vol. 124, Iss. 7, pp. 1237-1248
Open Access | Times Cited: 28
Integrating radiation therapy with targeted treatments for breast cancer: From bench to bedside
Icro Meattini, Lorenzo Livi, Nicla Lorito, et al.
Cancer Treatment Reviews (2022) Vol. 108, pp. 102417-102417
Closed Access | Times Cited: 19
Potent molecular-targeted therapies for advanced esophageal squamous cell carcinoma
Akira Ooki, Hiroki Osumi, Keisho Chin, et al.
Therapeutic Advances in Medical Oncology (2023) Vol. 15
Open Access | Times Cited: 12
Drug Delivery Opportunities in Esophageal Cancer: Current Treatments and Future Prospects
Robert C. Sabatelle, Yolonda L. Colson, Uma M. Sachdeva, et al.
Molecular Pharmaceutics (2024) Vol. 21, Iss. 7, pp. 3103-3120
Open Access | Times Cited: 4
CDK9 degradation Inhibits Gastroesophageal Cancer growth and Overcomes Radiation Resistance by Increasing Chromatin Accessibility and Downregulating YAP1/TEAD signaling
Yanting Zhang, Mikel Ghelfi, Xue Yu, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2025)
Closed Access
The Role of Yes‐Associated Protein in Inflammatory Diseases and Cancer
Bing Zhong, Jintao Du, Feng Liu, et al.
MedComm (2025) Vol. 6, Iss. 3
Open Access
Pharmacological regulators of Hippo pathway: Advances and challenges of drug development
Zhaobai Lao, Xin Chen, Bin Pan, et al.
The FASEB Journal (2025) Vol. 39, Iss. 6
Closed Access
Oral cancer: Current status of preclinical research
Kirti Mathur, Vandit Shah, Jigna Shah
Elsevier eBooks (2025), pp. 349-367
Closed Access
Cyclin-dependent kinase 4 and 6 inhibitors in breast cancer treatment
Zhengfei Guo, Rui Dong, Y. Wu, et al.
Oncogene (2025)
Closed Access
Integrated genomic profiling and modelling for risk stratification in patients with advanced oesophagogastric adenocarcinoma
Dapeng Hao, Siyuan He, Kazuto Harada, et al.
Gut (2020) Vol. 70, Iss. 11, pp. 2055-2065
Open Access | Times Cited: 30
Page 1 - Next Page

Scroll to top